ZIM
PGNX

Zacks Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Zacks Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-21,322
Closed -$145K – 690
2017
Q2 		$145K Buy
+21,322
New +$157K ﹤0.01% 560
2014
Q3 		– Sell
-77,322
Closed -$333K – 775
2014
Q2 		$333K Buy
+77,322
New +$295K 0.01% 544

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Zacks Investment Management's PGNX Position: Q3 2017 in Review

Zacks Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 21,322 shares — an estimated $145K sold.

Zacks Investment Management first reported a position in PGNX in Q2 2014 and held it in 2 quarters. The position peaked at $333K in Q2 2014. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • Zacks Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Zacks Investment Management sold 21,322 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $145K.
  • Zacks Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2014 and held it in 2 quarters.
  • Zacks Investment Management's Progenics Pharmaceuticals Inc position peaked at $333K in Q2 2014.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on Zacks Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.